Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.
Authors: Piwarski SA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Howard LE; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA., Paul MA; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Bachelder N; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Biocore, Charlottesville, Virginia, USA., LaCroix B; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Clayton A; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.; Flatiron Health, New York, New York, USA., Allen D; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Kephart J; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Armstrong AJ; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Patierno SR; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., George DJ; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Hyslop T; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Freedman JA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.
Source: Cancer [Cancer] 2026 Jun 01; Vol. 132 (11), pp. e70371.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.70371